Innovative Pharmaceutical Biotech Past Earnings Performance
Past criteria checks 2/6
Innovative Pharmaceutical Biotech has been growing earnings at an average annual rate of 34.6%, while the Trade Distributors industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 20.1% per year. Innovative Pharmaceutical Biotech's return on equity is 30.9%, and it has net margins of 1568.4%.
Key information
34.6%
Earnings growth rate
34.5%
EPS growth rate
| Trade Distributors Industry Growth | 7.5% |
| Revenue growth rate | -20.1% |
| Return on equity | 30.9% |
| Net Margin | 1,568.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?
Aug 12
Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)
Jan 05Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?
Feb 18Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.
Nov 26
Revenue & Expenses Breakdown
How Innovative Pharmaceutical Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 7 | 103 | 13 | 1 |
| 31 Dec 23 | 7 | 84 | 15 | 2 |
| 30 Sep 23 | 8 | 64 | 17 | 4 |
| 30 Jun 23 | 8 | -91 | 17 | 4 |
| 31 Mar 23 | 8 | -246 | 17 | 5 |
| 31 Dec 22 | 8 | -220 | 16 | 4 |
| 30 Sep 22 | 9 | -195 | 15 | 3 |
| 30 Jun 22 | 10 | -75 | 16 | 6 |
| 31 Mar 22 | 11 | 46 | 17 | 8 |
| 31 Dec 21 | 13 | 30 | 18 | 10 |
| 30 Sep 21 | 15 | 14 | 18 | 13 |
| 30 Jun 21 | 15 | -96 | 17 | 9 |
| 31 Mar 21 | 15 | -205 | 17 | 6 |
| 31 Dec 20 | 13 | -200 | 17 | 9 |
| 30 Sep 20 | 11 | -194 | 18 | 11 |
| 30 Jun 20 | 13 | -203 | 20 | 11 |
| 31 Mar 20 | 15 | -211 | 23 | 11 |
| 31 Dec 19 | 17 | -205 | 25 | 7 |
| 30 Sep 19 | 20 | -199 | 27 | 2 |
| 30 Jun 19 | 19 | -230 | 27 | 2 |
| 31 Mar 19 | 19 | -260 | 27 | 2 |
| 31 Dec 18 | 17 | -258 | 30 | 1 |
| 30 Sep 18 | 16 | -256 | 32 | 1 |
| 30 Jun 18 | 16 | -243 | 29 | 1 |
| 31 Mar 18 | 16 | -231 | 26 | 1 |
| 31 Dec 17 | 14 | -237 | 22 | 1 |
| 30 Sep 17 | 13 | -243 | 19 | 1 |
| 30 Jun 17 | 11 | -206 | 21 | 1 |
| 31 Mar 17 | 9 | -170 | 23 | 1 |
| 31 Dec 16 | 10 | -196 | 27 | 1 |
| 30 Sep 16 | 11 | -223 | 31 | 1 |
| 30 Jun 16 | 16 | -230 | 31 | 1 |
| 31 Mar 16 | 20 | -237 | 30 | 1 |
| 31 Dec 15 | 25 | -214 | 25 | 3 |
| 30 Sep 15 | 31 | -190 | 20 | 5 |
| 30 Jun 15 | 32 | -321 | 24 | 5 |
| 31 Mar 15 | 34 | -452 | 28 | 5 |
| 30 Sep 14 | 41 | -891 | 33 | 0 |
| 30 Jun 14 | 39 | -730 | 35 | 0 |
| 31 Mar 14 | 36 | -569 | 37 | 0 |
| 31 Dec 13 | 31 | -522 | 54 | 0 |
Quality Earnings: 399 has a large one-off gain of HK$330.2M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 399 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 399 has become profitable over the past 5 years, growing earnings by 34.6% per year.
Accelerating Growth: 399 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 399 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Trade Distributors industry (1%).
Return on Equity
High ROE: Whilst 399's Return on Equity (30.9%) is high, this metric is skewed due to their high level of debt.